Raymond James & Associates’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $21.9K | Sell |
6,344
-1,075
| -14% | -$3.71K | ﹤0.01% | 3884 |
|
|
2024
Q2 | $37.7K | Sell |
7,419
-167
| -2% | -$848 | ﹤0.01% | 3779 |
|
|
2024
Q1 | $64.3K | Sell |
7,586
-133
| -2% | -$1.13K | ﹤0.01% | 3743 |
|
|
2023
Q4 | $31.6K | Sell |
7,719
-1,472
| -16% | -$6.03K | ﹤0.01% | 3693 |
|
|
2023
Q3 | $27.6K | Sell |
9,191
-1,783
| -16% | -$5.35K | ﹤0.01% | 3676 |
|
|
2023
Q2 | $339K | Sell |
10,974
-6
| -0.1% | -$185 | ﹤0.01% | 3148 |
|
|
2023
Q1 | $544K | Sell |
10,980
-3,200
| -23% | -$158K | ﹤0.01% | 2851 |
|
|
2022
Q4 | $349K | Sell |
14,180
-2,140
| -13% | -$52.6K | ﹤0.01% | 3108 |
|
|
2022
Q3 | $1.08M | Buy |
16,320
+3,826
| +31% | +$254K | ﹤0.01% | 2338 |
|
|
2022
Q2 | $517K | Sell |
12,494
-200
| -2% | -$8.28K | ﹤0.01% | 2881 |
|
|
2022
Q1 | $640K | Buy |
12,694
+60
| +0.5% | +$3.03K | ﹤0.01% | 2899 |
|
|
2021
Q4 | $758K | Sell |
12,634
-684
| -5% | -$41K | ﹤0.01% | 2798 |
|
|
2021
Q3 | $659K | Buy |
13,318
+2
| +0% | +$99 | ﹤0.01% | 2855 |
|
|
2021
Q2 | $759K | Buy |
13,316
+271
| +2% | +$15.4K | ﹤0.01% | 2770 |
|
|
2021
Q1 | $749K | Sell |
13,045
-10,089
| -44% | -$579K | ﹤0.01% | 2696 |
|
|
2020
Q4 | $1.57M | Buy |
23,134
+3,889
| +20% | +$264K | ﹤0.01% | 2044 |
|
|
2020
Q3 | $4.88M | Buy |
19,245
+2,300
| +14% | +$584K | 0.01% | 1244 |
|
|
2020
Q2 | $2.85M | Buy |
16,945
+3,548
| +26% | +$597K | ﹤0.01% | 1508 |
|
|
2020
Q1 | $932K | Buy |
13,397
+5,290
| +65% | +$368K | ﹤0.01% | 2019 |
|
|
2019
Q4 | $520K | Buy |
8,107
+2,327
| +40% | +$149K | ﹤0.01% | 2694 |
|
|
2019
Q3 | $338K | Buy |
+5,780
| New | +$338K | ﹤0.01% | 2921 |
|